Trial Profile
Retrospective study comparing the effectiveness of recommended core agents in HIV/HCV co-infected patients in the U.S in the OPERA Observational Database
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2018
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Elvitegravir (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 29 Aug 2018 New trial record
- 27 Jul 2018 Results presented at the 22nd International AIDS Conference